This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a safe and effective way to improve cardiac function and left ventricular ejection fraction.
This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a safe and effective way to improve cardiac function and left ventricular ejection fraction.
A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
-
Hughes Spalding Children's Hospital, Atlanta, Georgia, United States, 30303
Egleston Children's Hospital, Atlanta, Georgia, United States, 30322
Emory Children's Center, Atlanta, Georgia, United States, 30322
Emory University Hospital, Atlanta, Georgia, United States, 30322
Scottish Rite Children's Hospital, Atlanta, Georgia, United States, 30342
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
4 Years to 30 Years
ALL
No
Emory University,
William Mahle, MD, PRINCIPAL_INVESTIGATOR, Emory University
2027-07